Oxford Biomedica (OXB)

Sector:

Pharma and Biotech

Index:

FTSE Small Cap

 398.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 445.00
  • 52 Week Low: 166.80
  • Currency: UK Pounds
  • Shares Issued: 105.36m
  • Volume: 0
  • Market Cap: £419.33m
  • RiskGrade: 125

OXB Overview

Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.

1 Day Chart (31-10-2024)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -205.7% -31.0%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 4.7 3.6
Pr/Book 5.4  
Latest F'cast
Revenue -36.0% 45.3%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

OXB Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 64.06 (20.89) (22.10)p n/a n/a n/a n/a 0.0%
31-Dec-20 87.73 (6.57) (7.81)p n/a n/a n/a n/a 0.0%
31-Dec-21 142.80 19.88 22.77p 54.0 n/a n/a n/a 0.0%
31-Dec-22 139.99 (45.98) (41.29)p n/a n/a n/a n/a 0.0%
31-Dec-23 89.54 (188.53) (163.11)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

OXB Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-24 130.07 (40.34) (38.95)p n/a n/a n/a n/a 0.0%
31-Dec-25 167.05 (18.94) (21.77)p n/a n/a n/a n/a 0.0%
31-Dec-26 211.33 5.32 (2.42)p n/a n/a n/a n/a 0.0%

Copyright © 2024 FactSet Research Systems Inc. All rights reserved.

OXB Company Announcements

Total Voting Rights 01-Nov-2024 07:00 RNS
Holding(s) in Company 31-Oct-2024 07:00 RNS
Block Listing Application 21-Oct-2024 09:47 RNS

OXB ShareCast News

Oxford Biomedica reports first-half revenue growth 23-Sep-2024 ShareCast
Oxford Biomedica still expecting small loss afte... 08-Aug-2024 ShareCast
Oxford Biomedica appoints new finance chief 17-Jul-2024 ShareCast

OXB Top Newspaper Links

Need to know: Opec cuts forecast ... Tesco cuts ... 16-Aug-2008 Times
Need to know 10-May-2008 Times
DSG International may be losing its spark 12-Feb-2008 Telegraph

Latest OXB Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

OXB Market Data

Currency UK Pounds
Share Price 398.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 445.00
52 Week Low 166.80
Volume 0
Shares Issued 105.36m
Market Cap £419.33m
RiskGrade 125

OXB Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
31.96% below the market average31.96% below the market average31.96% below the market average31.96% below the market average31.96% below the market average
16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average16.00% above the sector average
Price Trend
88.50% above the market average88.50% above the market average88.50% above the market average88.50% above the market average88.50% above the market average
96.00% above the sector average96.00% above the sector average96.00% above the sector average96.00% above the sector average96.00% above the sector average
Income Not Available
Growth
52.8% below the market average52.8% below the market average52.8% below the market average52.8% below the market average52.8% below the market average
52.94% below the sector average52.94% below the sector average52.94% below the sector average52.94% below the sector average52.94% below the sector average

What The Brokers Say

Strong Buy 1
Buy 3
Neutral 5
Sell 0
Strong Sell 0
Total 9
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

OXB Key Personnel

Chair Roch Doliveux
CEO Frank Mathias
CFO Lucinda (Lucy) Crabtree

Top of Page